A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Jean‐Yves Blay, Camille Schiffler, Olivier Bouché, Mehdi Brahmi, F. Duffaud, Maud Toulmonde, B. Landi, W. Lahlou, Diane Pannier, Emmanuelle Bompas, François Bertucci, L. Chaigneau, Olivier Collard, Marc Pracht, Clémence Henon, I. Ray-Coquard, K Armoun, Sébastien Salas, Mariella Spalato Ceruso, Antoine Adenis, B. Verret, Nicolas Penel, Camille Moreau-Bachelard, A. Italiano, Armelle Dufresne, Séverine Metzger, Sylvie Chabaud, David Pérol, A. Le Cesne
Topics & Concepts
MedicineGiSTImatinibInternal medicineAdjuvantOncologyStromal cellMyeloid leukemiaGastrointestinal Tumor Research and TreatmentGastrointestinal Bleeding Diagnosis and TreatmentMinimally Invasive Surgical Techniques